Actualités et Activités de MPM BioImpact
Dirigeants
Voir l'organigramme avec ses 29 principaux dirigeants
Biographies les plus recherchées chez MPM BioImpact
- Christiana Bardon, Managing Partner
- Ansbert Gadicke, Managing Partner
- Matthew Roden, Entrepreneur Partner
Changements de dirigeants chez MPM BioImpact
- Brian Shuster, a rejoint l'entreprise comme Entrepreneur Partner (publié le 9 janvier 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez MPM BioImpact.
Fond
MPM BioImpact a 1 573 concurrents dont BlackRock (Etats—Unis), KKR (Etats—Unis) et Vanguard (Etats—Unis).
Actualités en fusion/acquisition en Fond.
- Seven2 has announced the acquisition of HRK Lunis (publié le 3 avril 2025).
- Fluent a acquis RIV Capital (publié le 20 décembre 2024).
- RIV Capital and Fluent have announced they will merge (publié le 14 octobre 2024)..
Contacts en Fond
Actualités
Derniers communiqués de presse par MPM BioImpact
- DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved | DBV Technologies
- Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy | Cullin
- Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner
- MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
- Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | Syndax Pharmaceuticals, Inc.
- MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner
- AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE - Aktis
- AKTIS ONCOLOGY APPOINTS AKOS CZIBERE, MD, PhD, CHIEF MEDICAL OFFICER - Aktis
- NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de MPM BioImpact
- MPM BioImpact sur Wikipédia, Google News & Yahoo Finance en 1-click
- MPM BioImpact sur LinkedIn, Twitter & YouTube en 1-click
